Analytische Chemie
Filtern
Dokumenttyp
- Vortrag (2)
- Posterpräsentation (1)
Sprache
- Englisch (3)
Referierte Publikation
- nein (3)
Schlagworte
- Extracellular vesicles (EV) (3) (entfernen)
Organisationseinheit der BAM
Eingeladener Vortrag
- nein (2)
Extracellular vesicles (EV) are cell-derived particles in body fluids, which have excellent potential as next-generation biomarkers. The exploitation of EV requires reliable measurements, which is currently very difficult, as most EV are smaller than 200 nm. At present, flow cytometry (FCM) is the most appropriate technique for EV analysis in biological samples, as FCM is readily available in many clinical laboratories and allows to identify cell-specific EV at high throughput. However, due to technical variations between different FCM instruments, EV concentration measurements are currently not well comparable between most laboratories. Therefore, EV reference materials and standardized reference methods are urgently needed to calibrate flow rate, light scattering intensity, and fluorescence intensity of FCM in the sub-micrometer size range. This requires a better matching of the optical properties of calibration beads and EV as can be realized with current polystyrene calibration beads.
The EMPIR project 18HLT01 “MetVes II” aims to develop synthetic reference materials and traceable measurement methods to standardize EV measurements. The reference materials should resemble EV properties, so that calibrations are reliable and do not require a change of acquisition settings. Hence, the reference materials should contain particles with a traceable number concentration in the range of 109–1012 particles/mL to calibrate flow rate, a traceable size with discrete diameters between 50–1000 nm and a refractive index (RI) in the range of 1.37–1.42 to calibrate scattering intensity, and a traceable fluorescence intensity between 100–100,000 molecules of equivalent soluble fluorochromes (MESF). At BAM, various approaches to prepare such low-RI nanometer-sized reference materials will be studied, preliminary results of the primary characterization of these candidate reference particles will be presented, and possible applications besides FCM-based EV detection will be outlined.
The aim of task 1.4 within the EMPIR project 18HLT01 MetVesII is to produce low-RI solid particles with an effective RI between 1.37 and 1.42. To prepare these low-RI solid particles, polymer cores will be coated with a silica shell. Although the bulk RI of polymers, such as polystyrene (RI = 1.59) and PMMA (RI = 1.49), and fused silica (RI = 1.46) are higher than desired, an effective RI below 1.42 will be achieved by using a mesoporous silica shell with tuneable shell-thickness and a polymer core with sufficiently small size. This approach has four advantages: (1) monodisperse commercial polymer particles and silica shell chemistry are available, (2) low-RI solid particles will have a tuneable size and RI, (3) fluorescence can be added by incorporating fluorescent dyes into the polymer cores via an established staining procedure, and (4) fluorescent dyes within the polymer cores are shielded against influences from the sample matrix, e.g. fluorescence quenching effects altering the emission properties of the reference materials.
Standardisation of concentration measurements of extracellular vesicles for medical diagnoses
(2020)
Extracellular vesicles (EVs) are cell-derived particles in body fluids, which have excellent potential as next generation biomarkers for the early diagnosis of common diseases, such as cancer and thrombosis. This project aims to tap into the clinical potential of EVs by developing traceable measurements of number concentration, size distribution, refractive index (RI) and fluorescence intensity of cell-specific EVs in human blood and urine.
To realise our aims, we will develop synthetic reference materials with physical properties resembling EVs (WP1), instrumentation and procedures to standardise EV measurements in clinical laboratories (WP2), and ready-to-use biological test samples (WP3). These will then be evaluated in an inter-laboratory comparison study across a range (>20) of standard flow cytometers in clinical labs (WP4).